Interview with the CEO, President and Director and the VP of Investor Relations and Corporate Communications: Cynapsus Therapeutics Inc. (NASDAQ:CYNA)

Healthcare >> CEO Interviews >> January 15, 2016

Anthony Giovinazzo is a Director and the President and Chief Executive Officer of the Cynapsus Therapeutics Inc. He is an experienced biotech CEO with more than 18 years of experience in international pharmaceutical drug development, private and public financings, and M&A transactions. Mr. Giovinazzo has successfully managed Pre-IND, IND/CTA, end of Phase I-II, CTD/NDA submissions and negotiations with FDA, EMEA/CPMP. He has identified, licensed and overseen the development of eight biotech drug development candidates, preclinical to Phase III, for the treatment of Parkinson’s disease, Alzheimer’s, anxiety, neuropathic pain and nausea. Mr. Giovinazzo led the sale of Nova Molecular Diagnostics to Variagenics Inc. through the public listing of Variagenics that resulted in significant above-average returns to investors. As CEO, he also led the acquisition of Cita NeuroPharmaceuticals by Vernalis plc, which resulted in a substantial multiple return to venture investors. Mr. Giovinazzo holds a Chartered Director and Audit Committee Certification from The Directors College, where he was also a faculty member. He also was a business advisory board member of the National Research Council of Canada’s Genomics funding program. He is one of the inventors of the original APL-130277 intellectual property that was acquired by Cynapsus Therapeutics Inc. Profile

Kristen Galfetti is a Vice President of Investor Relations and Corporate Communications at Cynapsus Therapeutics Inc. Ms. Galfetti has over 20 years of experience in investor relations and corporate communications. She has held key roles developing communications programs for small and large health care companies. Ms. Galfetti’s recent corporate experience includes serving as Senior Director, Investor Relations at Sanofi, responsible for integrating the Genzyme Corporation investor relations program post-merger. Prior to Sanofi, Ms. Galfetti was Senior Director of Corporate Communications and Investor Relations at AMAG Pharmaceuticals, where she created the dual functioning department. Ms. Galfetti held roles of increasing responsibility at Genzyme Corporation, serving most recently as Senior Director, Investor Relations, assisting with integrating the tracking stock structure communications into a single business story. Ms. Galfetti received her MBA — with distinction — from Bentley University and a B.A. in political science from the University of Vermont. Profile

TWST: Can you provide an overview of the company and describe your technology?

Mr. Giovinazzo: Cynapsus Therapeutics is developing and commercializing a sublingual

Join for free to read a longer excerpt or purchase this article

Interview with the CEO, President and Director and the VP of Investor Relations and Corporate Communications: Cynapsus Therapeutics Inc. (NASDAQ:CYNA)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the CEO, President and Director and the VP of Investor Relations and Corporate Communications: Cynapsus Therapeutics Inc. (NASDAQ:CYNA)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS